B cell clonal expansion and mutation in the immunoglobulin heavy chain variable domain in response to Pfs230 and Pfs25 malaria vaccines. Issue 11 (October 2022)

• Record Type: Journal Article
• Authors: Coelho, Camila H.; Galson, Jacob D.; Trück, Johannes; Duffy, Patrick E.
• Is Part Of: International journal for parasitology. Volume 52:Issue 11(2022)
• Page Start: 707
• Page End: 710
• Publication Date: 2022-10
• Subjects: Pfs230 -- Pfs25 -- Malaria transmission-blocking vaccines -- B cell sequencing -- Clonal expansion -- VH mutation; Parasitology -- Periodicals; Parasitology -- Periodicals; Parasitologie -- Périodiques; Parasitology; Periodicals; Electronic journals; 571.999
• DOI: 10.1016/j.ijpara.2021.11.008
• Languages: English
• ISSNs: 0020-7519

Abstract

Graphical abstract: Highlights: Previously, we showed that immunogenicity and activity of Pfs230D1 vaccine is superior to Pfs25 in humans. Clonal expansion in IG heavy chains (VH) of Pfs230 B cells occurs with high frequency in response to Pfs230D1 vaccine. A stronger B cell response might contribute to superior Pfs230D1 activity. Abstract: Malaria transmission-blocking vaccines induce antibodies that target Plasmodium in the mosquito vector. We recently reported that Pfs230 vaccine achieves activity superior to Pfs25 in humans. Here, we describe clonal expansion in the variable region of immunoglobulin heavy chains (VH) of antigen-specific single B cells collected from humans immunised with Pfs230D1-EPA or Pfs25-EPA conjugate vaccines formulated in Alhydrogel®. Based on studies of CD27+ memory B cells following Pfs230 vaccination, clonal expansion and somatic hypermutation was seen in four of five subjects. Pfs25 did not induce sufficient CD27+ cells for sorting; based instead on CD19+ Pfs25-reactive B cells, clonal expansion was only seen in two of five subjects. Clonal expansions and mutations in Pfs230-specific single B cells combined with the enhanced activity of Pfs230 antibodies by complement, might justify the outstanding activity of Pfs230D1 as a TBV candidate.